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THE FDA GUIDANCE DOCUMENT FOR
MEDICAL MOBILE APPS AND ITS IMPACT ON
INNOVATION: BRINGING THE PROMISE OF A
NEW WAY TO LOOK AT MEDICINE CLOSER,
OR PUSHING IT FURTHER?
Ioana Ciopraga*
INTRODUCTION
Six years after the launch of the iPhone, it is almost impossible to
conceive what our lives would be like without our mobile devices.1 And,
regardless of your field of interest, chances are “there’s [at least] an app for
that.”2 According to Portio Research, 1.2 billion people used mobile apps
worldwide in 2012 and approximately 4.4 billion people will be using
mobile apps by 2017. 3 While the total number of apps currently out on the
market is hard to calculate, there are over 1,600,000 mobile apps only
between Apple’s App Store and Google’s Play Store.4
Mobile apps are no longer limited to games, but have also become
players in fields such as education and medicine. The World Health
Organization defines mobile health as “medical and public health practice
supported by mobile devices, such as mobile phones, patient monitoring
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1.

See generally Olivia Williams, Why are we so frightened of NOT having a mobile
phone?,
DAILYMAIL
Aug.
25,
2013,
4:05
PM,
http://www.dailymail.co.uk/news/article-2401854/Why-frightened-NOT-havingmobile-phone.html (suggesting that over half of the population may suffer from
nomophobia: the fear of being without a mobile phone).

2.

THERE’S AN APP FOR THAT, Registration No. 4091498 (a trademark owned by
Apple implying that for any task or purpose, there is an app for that task or
purpose).

3.

MOBITHINKING, Global mobile statistics 2013 Section E: Mobile apps, app stores,
pricing and failure rates, May 2013, http://mobithinking.com/mobile-marketingtools/latest-mobile-stats/e#appusers
(citing
a
blog
post
from
http://www.portioresearch.com/).

4.

Top iOS and Android apps largely absent on Windows Phone and BlackBerry 10,
CANALYS (May 23, 2013), http://www.canalys.com/newsroom/top-ios-andandroid-apps-largely-absent-windows-phone-and-blackberry-10 (“[T]he Apple
App Store and Google Play each boast more than 800,000 apps.”).
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devices, personal digital assistants (PDAs), and other wireless devices.”5
There are currently over 43,000 healthcare related apps in the iTunes store
alone,6 and, according to Research2Guidance, 500 million people will be
using healthcare mobile applications in 2015 globally.7
This Note critiques the guidance document released by the Food and
Drug Administration (“FDA”) in connection with the medical mobile apps
it intends to regulate and the regulations that govern medical mobile apps.
Specifically, the main argument of this Note is that, while the document is
clearly a step in the right direction, significantly more guidance, focused on
the characteristics of this new field, such as the rapid change of mobile
technology, and on the transformational impact on healthcare of health IT
in general and mHealth in particular, should follow soon. Part I provides an
overview of the guidance document, with a focus on the FDA’s attempt to
find the right balance between regulating apps that could potentially be
harmful, and trying to promote innovation. Part II reviews the FDA
regulations for medical devices in general, which the FDA used in its
guidance document for medical mobile apps. Part III discusses ambiguities
in the guidance document, the difficulties mobile app developers may
encounter in trying to comply with it, the huge gap between the ability of
conventional medical device manufacturers and that of medical mobile app
manufacturers to go through the premarket approval process, and how the
way the FDA intends to regulate medical mobile apps may ultimately
impact innovation in the field. Part IV looks at potential solutions to
improve the current regulations and strike the balance between ensuring
safety and supporting innovation, and argues for a change in the way the
FDA approaches regulation of mobile medical apps, which should
incorporate a clear reflection of a field that is constantly evolving at a very
fast pace, with very different players than the traditional medical device
manufacturers, and for which a 40-year old framework is simply outdated.

I. THE PROBLEM: MOBILE APPS AS MEDICAL DEVICES
A. Mobile Apps.
The Federal Food, Drug, and Cosmetic Act defines a medical device as
“an instrument, apparatus, implement, machine, contrivance, implant, in
vitro reagent, or other similar or related article, including any component,
5.

WORLD HEALTH ORG., MHEALTH: NEW HORIZONS FOR HEALTH THROUGH MOBILE
TECHNOLOGIES
(2011),
available
at
http://whqlibdoc.who.int/publications/2011/9789241564250_eng.pdf.

6.

Press Release, IMS Institute for Healthcare Informatics, IMS Health Identifies
Opportunities for Mobile Healthcare Apps to Drive Patient Engagement, Enhance
Delivery
of
Care
(Oct.
30,
2013),
available
at
http://www.imshealth.com/portal/site/imshealth/ (follow “View All News”
hyperlink, then navigate through list to “30 Oct 2013”).

7.

Ralf-Gordon Jahns, 500m people will be using healthcare mobile applications in
2015,
RESEARCH2GUIDANCE
(Nov.
10,
2010),
http://www.research2guidance.com/500m-people-will-be-using-healthcare-mobileapplications-in-2015/.
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part, or accessory, which is … intended for use in the diagnosis of disease
or other conditions, or in the cure, mitigation, treatment, or prevention of
disease, in man or other animals, or … intended to affect the structure or
any function of the body.”8
Before the world could even comprehend the idea of mobile apps as
medical devices, the first mobile apps were built by handset manufacturers
and carriers, and were part of the pre-installed software stack. And while
people who bought the same headset used to have the same exact device,
no two people today have the same exact mobile phone because as soon as
they get the device they are able to customize it based on their needs,
interests and preferences.9 Nowadays, most of us also know someone who
has built or is thinking about building an app. The change was driven by
how mobile devices have evolved in terms of technology advancements, by
manufacturers understanding the importance of giving access to the
internal design of handsets, and by the emergence of proprietary platforms
such as iOS and Android, on which developers can freely create apps not
just for smartphones, but for a plethora of mobile devices. With over “one
billion active smartphones and tablets [currently being active] globally, …
[analysts] expect [the number] to reach two billion in 2014.”10
Using mobile health related apps was a natural progression for today’s
consumers, who have been leveraging the Internet for years to look up
medical information online. According to Pew Internet and America Life
Project, 81% of American adults use the Internet, and 72% of Internet users
looked online for health related information within the past year.11 As of
April 2012, 19% of smartphone owners had downloaded an app
specifically to track or manage health.12 We use our mobile devices to
connect to our friends, our families, our business partners, so using them to
connect to our healthcare providers and manage our health is only logical.
As concluded by the GSM Association “[mHealth] solutions can help
healthcare providers deliver better, more consistent, coordinated and more
efficient healthcare, where and how it is needed, increase access to health
services to remote or under-served communities and empower individuals
8.

Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 321 (2009).

9.

Gary Marshall, 10 Amazing Things You Never Knew a Smartphone Could Do,
TECHRADAR (Aug. 26, 2013), http://www.techradar.com/us/news/phone-andcommunications/mobile-phones/10-amazing-things-you-never-knew-asmartphone-could-do-1175046 (“[M]anufacturers provide the hardware, and we
turn them into magical machines with apps that transform them into musical
instruments or games consoles, business machines or cat video players”).

10. Mary Ellen Gordon, India, China and the Map to Two Billion Connected Devices,
FLURRY (Jun. 10, 2013), http://blog.flurry.com/bid/97962/India-China-and-theMap-to-Two-Billion-Connected-Devices.
11. Susannah Fox & Maeve Duggan, Health Online 2013, PEW INTERNET (Jan. 15,
2013), http://www.pewinternet.org/~/media//Files/Reports/PIP_HealthOnline.pdf.
12. Susannah Fox & Maeve Duggan, Mobile Health 2012, Pew Internet (Nov. 8,
2012),
http://www.pewinternet.org/files/oldmedia//Files/Reports/2012/PIP_MobileHealth2012_FINAL.pdf.
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to manage their own health more proactively and effectively.”13 By 2017,
according to Research and Markets, half of the 3.4 billion smartphone or
tablet users worldwide will use mobile health apps.14
“[T]he use of mobile devices in the delivery of healthcare and in
obtaining healthcare knowledge [has become] ubiquitous.”15 In light of the
Affordable Care Act, mobile devices are also one of the most promising
tools in achieving an important goal of Accountable Care Organizations16,
by reinforcing the best behavior in patients, reducing costs, and shifting the
focus from just treatment to wellness and prevention. Mobile devices and
the mobile apps they allow us to use are ideally suited to take healthcare
outside of the hospital environment and begin a new age of remote
medicine that has the potential to drive healthcare costs down while
empowering the patients to become engaged in their health and wellness.
In 2012, there were 828 companies in the high tech medical device
industry, generating over $60 billion, and employing over 88,000 people,17
and the top three companies (Medtronic, General Electric, and St. Jude
Medical) controlled 32% of the market share.18 By contrast, according to
the Wall Street Journal,19 the average app developer today is 29 years old
or younger, 40% of app developers work alone, while 27% work at 2-3
person firms, with 34% making less than $15,000 from app development,
65% making less than $35,000, and only 12% making $100,000 or more.

13. GSM ASS’N, mHealth and the EU Regulatory Framework for Medical Devices,
http://www.gsma.com/connectedliving/wpcontent/uploads/2012/03/mHealth_Regulatory_medicaldevices_10_12.pdf
(last
visited Mar. 16, 2014).
14. Erin McCann, MHealth Enters Consumer Golden Age, HEALTHCARE IT NEWS
(Oct. 25, 2013), http://www.healthcareitnews.com/news/mhealth-enters-consumergolden-age.
15. Paul De Muro, Mobile Medical Applications and the Affordable Care Act, THE
LUND REPORT (Dec 2, 2013), http://www.thelundreport.org/content/mobilemedical-applications-and-affordable-care-act (arguing that “[u]nder health reform,
facilitated by the Affordable Care Act, (ACA) many can envision that
mobile medical apps will become increasingly important in this new patientcentered care environment).
16. American College of Physicians, Joint Principles for Accountable Care
Organizations,
,
http://www.acponline.org/acp_policy/policies/joint_principles_accountable_care_o
rganizations_2010.pdf (last visited Mar. 16, 2014) (“Accountable Care
Organizations must align mutual accountability at all levels, fostered by
transparency and focused on health promotion and healthy development, disease
prevention, care management, and care coordination”).
17. Han Zhong, Primer: The Medical Device Industry (Jun. 2012),
http://americanactionforum.org/sites/default/files/OHC_MedDevIndPrimer.pdf.
18. Id.
19. Scott Austin, The Surprising Numbers Behind Apps, Wall St. J., Mar. 11, 2013,
http://blogs.wsj.com/digits/2013/03/11/the-surprising-numbers-behind-apps/.
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B. FDA Guidance.
On September 25, 2013, the FDA released its final guidance document
pertaining to mobile medical apps it intends to regulate. While the FDA
acknowledges that “[m]obile apps are unleashing amazing creativity, and
[it] intend[s] to encourage these exciting innovations,”20 its guidance
regarding mobile medical apps may slow down or deter the very innovation
it intends to encourage. A summary of the guidance is provided below.
Most analysts welcomed the newly released guidance, as it brought
much needed clarity compared to the draft guidelines released by the FDA
back in 2011.21 Morgan Reed, the executive director for the Association for
Competitive Technology said that the new guidelines prove that the FDA
“recognized that they aren’t going to tell us how to innovate.”22 In theory,
this should be good news for app developers and for the industry in
general. However, the FDA applied the same approach it used in regulating
medical devices in general to medical mobile apps, which could prove
problematic and counterproductive in the long run. Part III discusses this in
detail.

1. Apps That Are Not Medical Devices
The apps included under this category are apps that “could be used in a
healthcare environment, in clinical care or patient management, but are not
considered medical devices.”23 Since these apps are not considered medical
devices, the FDA will not regulate them. The list of examples included in
the guidance document24 by the FDA indicates that the apps most likely to
fall under this category are educational and informational, and are “not
intended for use in the diagnosis of disease or other conditions, or in the
cure, mitigation, treatment, or prevention of disease.”25 For example, these
types of apps provide users and healthcare professionals with access to
medical literature as well as commonly used reference information, can be
training tools for healthcare providers, or help patients interact with their
healthcare providers via different communications mechanism, as long as
they are not intended specifically for medical use. If it simply informs or

20. Keeping Up with Progress in Mobile Medical Apps, FDA CONSUMER HEALTH
INFO. (FDA, Silver Spring, MD), Sept. 2013, at 2.
21. Bradley Merrill Thompson, FDA (Finally) Returns Industry’s Calls for Mobile
Medical Apps Guidance, MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY ONLINE
(Sep. 23, 2013), http://www.mddionline.com/blog/devicetalk/fda-finally-returnsindustrys-calls-mobile-medical-apps-guidance.
22. Diana Manos, 3 Surprises in FDA’s Mobile Medical Apps Final Guidance,
GOVERNMENT HEALTH IT (Nov. 6, 2013), http://www.govhealthit.com/news/3surprises-fdas-mobile-medical-apps-final-guidance.
23. FDA, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY AND FOOD
DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at 12, (Sept. 25, 2013).
24. Id.
25. Id.
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educates, a healthcare related mobile app is not considered a medical
device, and the FDA will not regulate it.

2. Apps That Are Medical Devices but over Which the FDA Will
Exercise Enforcement Discretion
In the case of apps that may be considered medical devices, but pose a
low risk to patients, the FDA does not intend to enforce the requirements
under the Food, Drug and Cosmetic Act.26 These types of apps go beyond
information or education, and are mostly apps that allow patients to selfmanage their conditions, organize information related to their health, and
communicate with their health care providers, as well as apps that automate
simple tasks for health care providers.27 The key characteristic of the apps
included in this category is that they do not provide “specific treatment or
treatment suggestions.”28 Classified under this category are apps that track
the user’s use of medication or medical devices, collect data from these
medical devices (either electronically or data the use inputs manually),
track health episodes such as asthma attacks and hospitalizations, and
provide reminders and means to communicate with the user’s healthcare
providers. In using the apps that fall under this category, the user is
exposed to no risk or a minimal amount of risk, so the FDA will only
exercise enforcement discretion.

3. Apps That Are Medical Devices and over Which the FDA Will
Exercise Regulatory Authority
The FDA stated that it would focus its oversight on “medical mobile
apps that meet the definition of device in the Federal Food, Drug and
Cosmetic Act29 and are intended to transform a mobile device into a
medical device regulated by the FDA, or be used as an accessory to a
medical device regulated by the FDA.”30 The FDA explained that “[the]
intended use of a mobile app determines whether it meets the definition of
a ‘device.’”31 The intended use may be shown, for example, by “labeling
claims, advertising matter, or oral or written statements by [the persons
legally responsible for the labeling of devices], or by the circumstances that
26. Id. at 16
27. Id.
28. Id.
29. Federal Food, Drug, and Cosmetic Act of 1938, 21 U.S.C. § 321 (2009) (defining a
medical device as “an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article, including any
component, part, or accessory, which is … intended for use in the diagnosis of
disease or other conditions, or in the cure, mitigation, treatment, or prevention of
disease, in man or other animals, or intended to affect the structure or any function
of the body of man or other animals ….”).
30. FDA, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY AND FOOD
DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at 4, (Sept. 25, 2013).
31. Id.
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the article is, with the knowledge of such persons or their representatives,
offered and used for a purpose for which it is neither labeled nor
advertised.”32 Therefore, the FDA will consider a mobile app a medical
device if it performs the functions of a medical device. If an app performs a
medical function (diagnosing or recommending a treatment for example),
then the app is a medical device and therefore subject to FDA’s oversight.
In its guidance document, the FDA divided the types of medical
mobile apps that will be subject to its oversight into three categories.
Mobile apps that are extensions of a medical device are those mobile apps
that connect to an existing medical device in order to control the device or
display, analyze, or transmit patient-specific medical device data.33 Such an
app would be, for example, a mobile app that controls the inflation and
deflation of the blood pressure cuff of a traditional blood pressure monitor.
Mobile apps that transform the mobile platform into a medical device
through the use of attachments, sensors or display screens will be required
to “comply with the device classification associated with the transformed
platform.”34 Such an app would be, for example, a mobile app that
performs the role of a blood glucose meter with a use of an attachment
capable of reading blood glucose strips. Mobile apps that become a
regulated medical device (software) by performing patient-specific
analysis, providing diagnosis, or treatment recommendations are apps that
are “similar to or perform the same function as those types of software
devices that have been previously cleared or approved.”35 Such an app
would be, for example, a mobile app that uses patient-specific parameters
to calculate or create a dosage plan for radiation therapy.
The FDA was responsive to the comments it received regarding the
draft guidance published in July 2011, and, after collecting and analyzing
input, it included multiple examples for each category,36 to help app
manufacturers navigate the guidance document and identify which category
their apps will fall under.37 In brief, the FDA will only regulate mobile
apps that would qualify as medical devices, either on their own or in
combination with an existent medical device. These apps will have to go
through the same review system as the one the FDA has been employing
for regular medical devices since 1976. Part II looks at the review system
for medical devices.

32. 21 C.F.R. § 801.4 (2007).
33. FDA, supra note 30, at 8.
34. Id. at 9.
35. Id.
36. FDA, supra note 20, at 1-2.
37. Manos, supra note 22 (“[T]he guidance is chock full of anecdotes that provided
better clarity”).
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II. FDA REGULATIONS FOR MEDICAL DEVICES
The FDA has defined three classes of regulatory control for medical
devices under the Federal Food, Drug, and Cosmetic Act.38 As indicated by
the guidance document, mobile medical apps that will be subject to FDA’s
oversight will be assigned to one of the same three classes described below.

A. Class I
Medical devices classified under Class I are subject only to general
controls.39 While general controls apply to all three classes, they are the
only level of control that applies to medical devices in Class I. General
controls for medical devices include device registration and listing, labeling
requirements, records and reports, as well as good manufacturing
practices.40 While general controls also include a requirement for
premarket notification,41 FDA has exempted almost all Class I devices,
with the exception of devices referred to as of Reserved Devices, from the
premarket notification requirement.42 General controls also mean that the
manufacturer has to abide by the good manufacturing practice (“GMP”)
requirements set forth in Title 21 of the Code of Federal Regulations.43
Mobile apps that qualify as Class I devices will thus be subjected to
general controls alone, and the vast majority will be exempt from the
premarket notification requirement. A premarket notification, also referred
to as a 510(k), “is a premarketing submission made to FDA to demonstrate
that the device to be marketed is safe and effective by proving substantial
equivalence (SE) to a legally marketed device (predicate device) that is not
subject to Premarket Approval (PMA).”44 The document issued by the
FDA with regard to mobile medical applications lists premarket
notification under general controls required for Class I devices, without
38. 21 C.F.R. § 860.3(c) (2007).
39. 21 C.F.R. § 860.3(c)(1) (2007) (“A device is in class I if (i) general controls are
sufficient to provide reasonable assurance of the safety and effectiveness of the
device, or (ii) there is insufficient information from which to determine that
general controls are sufficient to provide reasonable assurance of the safety and
effectiveness of the device or to establish special controls to provide such
assurance, but the device is not life-supporting or life-sustaining or for a use which
is of substantial importance in preventing impairment of human health, and which
does not present a potential unreasonable risk of illness of injury”).
40. FDA, General Controls for Medical Devices (May 13, 2009),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/Ge
neralandSpecialControls/ucm055910.htm.
41. 21 C.F.R. § 807.81 (2007).
42. FDA, Medical Device Exemptions 510(k) and GMP Requirements (Jan. 20, 2014),
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/315.cfm.
43. 21 C.F.R. § 820 (2007).
44. FDA,
How
to
Find
a
Predicate
Device
(Dec.
20,
2013),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarket
YourDevice/PremarketSubmissions/PremarketNotification510k/ucm134571.htm.
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specifying the fact that most mobile medical apps that would be considered
Class I devices would also be exempt from the premarket notification
requirement.
The only indication that the premarket notification for Class I devices
may not be an absolute requirement is the fact that it is listed as a standalone requirement for mobile medical apps in Class II.45 However, a
medical mobile app in Class I may still be considered a reserved device, for
which the premarket notification will not be waived. The FDA
Modernization Act of 1997 explains in section 206 that “the exception …
does not apply to any [C]lass I device that is intended for a use which is of
substantial importance in preventing impairment of human health, or to any
[C]lass I device that presents a potential unreasonable risk of illness or
injury.”46 Such devices remain subject to premarket notification. The
mobile app manufacturer must consult the list of reserved devices to make
sure the mobile app does not require premarket notification.

B. Class II
Medical devices classified under Class II are subject to general
controls, special controls and premarket notification.47 Through the
premarket notification, “[s]ubmitters must compare their 510(k) device to a
similar legally marketed U.S. device.”48 The similar device is called a
“predicate device,”49 and it can be a device that was marketed before May
28, 1976, a device cleared under the 510(k), a device that was downclassified from Class III to Class I or II, or a 510(k) exempt device.50 The
predicate device does not have to be identical to the device in question.
What the 510(k) must establish is substantial equivalence with the
predicate device, which can be accomplished by analyzing the “intended
use, design, energy used or delivered, materials, performance, safety,

45. FDA, supra note 23, at 12.
46. 21 U.S.C. § 360 (2009).
47. 21 C.F.R. § 860.3 (2007) (“A device is in class II if general controls alone are
insufficient to provide reasonable assurance of its safety and effectiveness and
there is sufficient information to establish special controls, including the
promulgation of performance standards, postmarket surveillance, patient registries,
development and dissemination of guidance documents (including guidance on the
submission of clinical data in premarket notification submissions in accordance
with section 510(k) of the act), recommendations, and other appropriate actions as
the Commissioner deems necessary to provide such assurance. For a device that is
purported or represented to be for use in supporting or sustaining human life, the
Commissioner shall examine and identify the special controls, if any, that are
necessary to provide adequate assurance of safety and effectiveness and describe
how such controls provide such assurance”).
48. FDA, supra note 44.
49. Id.
50. Id.
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effectiveness, labeling, biocompatibility, standards, and other applicable
characteristics.”51
Grandfathered devices are those devices that were marketed prior to
May 28, 1976, have not been significantly modified since then, and “for
which a regulation requiring a premarket approval (PMA) application has
not been published by FDA.”52

C. Class III
Medical devices classified under Class III are subject to premarket
approval. These are the highest risk devices. Any new device that was not
marketed before 1976 or that cannot claim substantial similarity with a
predicate device is automatically a Class III device as well.53 This is
regardless of the level of risk posed by the device. A wholly innovative
device that addresses issues traditional devices did not or were not able to
address, would thus be classified as Class III, simply because of its novelty,
even if it poses no risk or a minimal amount of risk for the patient.
Premarket approval is a great thing both for patients and for
manufacturers. It ensures patients are using a device that has been
thoroughly tested and deemed safe by the FDA, and it shields
manufacturers from legal action. In 2008, the Supreme Court in Riegel v.
Medtronic stated that medical device manufacturers are immune from
liability for personal injuries as long as the FDA approved the device
before it was marketed and it meets the Agency’s specifications.54 The
Supreme Court’s decision in Riegel does not impact devices that were
approved through the 510(k) process, but only those that got FDA
premarket approval.

III. REGULATING MEDICAL APPS AS MEDICAL DEVICES
A. Problems with the Current Regulation
1. Mobile Apps as Class I Medical Devices
For the average app developer, consulting and understanding the steps
he/she needs to follow to determine whether the app he is building will be
regulated or not, and what he needs to do to abide by the FDA regulations
may not be so easy, despite the newly released guidelines. Consider
Breathometer, one of the first breathalyzers for smartphones. The portable
device connects to any smartphone and “can transform your smartphone
51. Id.
52. Id.
53. 21 C.F.R. § 860.3 (2007) (“A device is in class III if insufficient information exists
to determine that general controls are sufficient to provide reasonable assurance of
its safety and effectiveness or that application of special controls … would provide
such assurance and if, in addition, the device is life-supporting or life-sustaining,
or for a use which is of substantial importance in preventing impairment of human
health, or if the device presents a potential unreasonable risk of illness or injury”).
54. Riegel v. Medtronic, Inc., 552 U.S. 312 (2008).
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into a breathalyzer within seconds — helping you monitor your alcohol
consumption, giving you the power to make smarter decisions when
drinking.”55 The keychain-sized device “plugs into the phone’s headphone
jack and can connect to both Android and Apple apps [providing] … a way
for people to check whether they’re too drunk to drive home.”56
According to the FDA breath-alcohol test systems are medical
devices.57 Breathometer qualifies as a medical app that will be the focus of
FDA oversight. It is a mobile app that “transforms a mobile platform into a
regulated medical device by using attachments, display screens, sensors, or
other such methods.”58 Breathometer also qualifies as a Class I medical
mobile app,59 subject to general controls, and it would also appear that it
qualifies as a reserved medical device.60 Therefore, under the general
controls specifications, Breathometer appears to be among the devices that
are not exempted from the premarket notification requirement and will
have to obtain the 510(k) clearance. Breathometer Inc. has registered
Breathometer with the FDA, with the product code DJZ, which indicates
under the “submission type” field that the device is subject to enforcement
discretion.61
There are two problems with how the guidelines for mobile medical
apps apply to an app like Breathometer. First, the guidance document for
medical mobile apps specifies that for mobile apps for which FDA intends
to exercise enforcement discretion, “the FDA intends not to pursue
enforcement action for violations of the FD&C Act and applicable
regulations by a manufacturer of a mobile app that meets the definition of a
device in section 201(h) of the FD&C Act.”62 Thus, the app developer who
sees Breathometer’s FDA submission could easily conclude that the FDA
does not intend to pursue enforcement action for this category of mobile
apps. Yet, a Breathalyzer is a Class I device, and the developer needs to
comply with the general controls specified by the FDA. The app developer
55. BREATHOMETER, https://www.breathometer.com/ (last visited Mar. 16, 2014).
56. Jonah Cornstock, Six Attempts at a Smartphone-Connected Breathalyzer,
MOBIHEALTHNEWS (Jun. 10, 2013), http://mobihealthnews.com/22907/sixattempts-at-a-smartphone-connected-breathalyzer/4/.
57. 21 C.F.R. § 862.3050 (2007) (“A breath-alcohol test system is a device intended to
measure alcohol in the human breath. Measurements obtained by this device are
used in the diagnosis of alcohol intoxication”).
58. FDA, supra note 23, at 8.
59. Id.
60. FDA,
Reserved
Medical
Devices
(Jan.
20,
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/3151.cfm.

2014),

61. FDA,
Product
Classification
(Jan.
20,
2014),
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=D
JZ.
62. FDA, CHRH 1741, MOBILE MEDICAL APPLICATIONS GUIDANCE FOR INDUSTRY
AND FOOD AND DRUG ADMINISTRATION STAFF, 2013 WL 5634256 at *7, n. 18
(2013) [hereinafter MOBILE MEDICAL APPLICATIONS].
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who wants to develop an app similar to Breathometer will likely be
confused by the fact that the guidance document for medical mobile apps
indicates that a mobile breathalyzer of this type would be the focus of the
FDA’s regulatory oversight,63 while a search in the FDA’s database will
reveal that the FDA seemingly only exercises enforcement discretion for
medical devices with the product code DJZ.64
The problem arises from the use of the term “enforcement discretion”
by the FDA with two different meanings. In the first instance, as explained
by the guidance document for medical mobile apps, enforcement discretion
means that the FDA “does not intend to enforce requirements under the
FD&C Act.”65 In the second instance, as used by the FDA under the DJZ
product code, it means that the FDA will exercise enforcement discretion
only with regards to the premarket notification requirement for some
devices in Class I and Class II that qualify as “reserved devices.” While it
appears that breathalyzers and other medical devices initially deemed
“reserved devices” require 510(k) clearance, in December, 2011, the FDA
released a guidance document instructing FDA staff that it intends the
down-classification and exemption from the 510(k) requirement for a series
of devices whose “safety and effectiveness … is sufficiently well
established and they have sufficiently controlled risks that general controls
are sufficient and a 510(k) review is not necessary.”66 Devices under
product code DJZ were among those the FDA intends to take off the
“reserved devices” list through an amendment.67 This confusion could lead
the app developer to market his application, without complying with any of
the general controls necessary for Class I, and thus violate the FDA’s
guidance document for medical mobile apps.
A second problem is that, while the FDA intends to exempt devices
such as breathalyzers from the premarket notification requirement, the list
of “reserved devices” on the FDA’s website still includes all the devices
originally listed in the “reserved device” category, indicating that all the
“reserved devices” have to comply with the premarket notification
requirement. If the app developer chooses this venue of research, he will
likely go through the 510(k) clearance process, despite the fact that the
FDA no longer enforces it for this type of devices. Given the profile of the
average developer,68 and the type of resources available to the average
63. Id. at *9 (providing that apps which transform the mobile platform into a regulated
device are amongst the focus of FDA regulatory oversight).
64. FDA, Product Classification Database, supra note 61.
65. FDA, MOBILE MEDICAL APPLICATIONS, supra note 62, at *10 (2013).
66. FDA, Guidance for Industry and Food and Drug Administration Staff Enforcement Policy for Premarket Notification Requirements for Certain In Vitro
Diagnostic
and
Radiology
Devices
(Dec.
20,
2011),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDoc
uments/ucm283904.htm.
67. Id.
68. See supra Part I.
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developer, this could either impose an unnecessary burden on the
developer, or completely dissuade him from developing and marketing the
app.
The Breathometer/breathalyzer example illustrates an instance where
the information in the guidance document for medical mobile apps is
insufficient and can lead the app manufacturer, who is the ultimate
recipient of the document, to either waste resources or ignore the FDA’s
requirements for the class of devices the app belongs to. The inconsistency
of the term “enforcement discretion” and the lack of clarity in the newly
released guidance document for medical mobile apps can thus lead to
undesirable results that can ultimately discourage innovation. In the
example of the mobile Breathalyzer, if the information provided by the
FDA in the guidance document and on its website were consistent and
clear, the general controls required under Class I should be fairly easily
complied with by any app manufacturer. The system is more complicated
for Class II devices, for which “general controls alone are insufficient to
provide reasonable assurance of [their] safety and effectiveness.”69

2. Mobile Apps as Class II Medical Devices
Mobile medical apps such as an electronic stethoscope or an ECG
controlled through a mobile device would be classified as Class II
devices.70 The manufacturers of the apps would thus have to go through the
510(k) clearance process before they are able to market the mobile medical
apps. And while the process has been in place for a while and may appear
to be streamlined for traditional medical devices, the same may not be true
for mobile medical apps. Given the various new parameters mobile devices
are able to track and use (such as location, spatial positioning, and a whole
set of data that they can obtain in real time by connecting to the Internet
wherever the user may be), the manufacturers of medical mobile apps that
can incorporate and take advantage of them will likely not be able to easily
find a predicate device. The process is lengthy, difficult, and expensive,
and substantial similarity, while not requiring an identical device, can be
difficult to prove.
A 2010 study by Stanford University and the National Venture Capital
Association showed that “the average total cost … to bring a low- to
moderate-risk 510(k) product from concept to clearance was approximately
$31 million, with $24 million spent on FDA dependent and/or related
activities.”71 For the traditional medical device manufacturer, big
companies like Phillips or Omron, this would be part of the cost of doing
69. 21 C.F.R. § 860.3 (2007).
70. FDA, MOBILE MEDICAL APPLICATIONS, supra note 62, at *10 (2013).
71. Josh Makower, Aabed Meer & Lyn Denend, FDA Impact on U.S. Medical
Technology Innovation, NATIONAL VENTURE CAPITAL ASSOCIATION, at 28, Nov.
2010,
available
at
http://www.eucomed.org/uploads/Press%20Releases/FDA%20impact%20on%20U
.S.%20Medical%20Technology%20Innovation.pdf.
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business. But going back to the average app developer, this is unattainable
for most, and improbable even if they manage to secure investment.
According to a report by research-focused investment bank Rutberg &
Company, between January and August 2013, fifty companies in mHealth
have managed to attract venture capital funding of $310 million72, a
significant increase from the same period in 2012. Still, this averages
approximately $6 million per company, a number that is nowhere close to
the expenses estimated by Stanford in connection with getting the FDA’s
510(k) clearance. While acknowledging the tremendous innovation that
comes from startups in this field, Rajiv Chand, Managing Directors and
Head of Research at Rutberg & Company cautions “that it is very difficult
to grow companies within the sector and that although several companies
are emerging as breakout leaders, most are struggling with adoption and/or
revenue growth.”73
Even considering that the financial obstacle could be surpassed,
demonstrating substantial similarity could prove as much of a hurdle in the
case of mobile medical apps. In a field that is constantly changing, time is
of the essence. And the 510(k) can not only be a very difficult process, but
it can also stretch past the 90 days the FDA estimates are necessary to
determine substantial equivalency. 74
MIM, the first mobile medical app to get FDA approval,75 provides the
perfect example. It took the company two and a half years to get FDA
510(k) clearance for an iOS viewer for CT and MRI images.76 While the
company had gone through the 510(k) process before for different nonmobile devices, without any difficulties, tackling the 510(k) for a mobile
medical device proved to be a different story.77 Not only did the FDA close
the company’s submission for lack of “substantial equivalence to a
predicate device,” although the company had used as predicate device one
of their own viewing software,78 but the app “got bumped up to Class 3
Premarket Approval which is the same classification as high risk devices,

72. Greg Slabodkin, VC Investment in mHealth Surpasses Last Year, FIERCE MOBILE
HEALTHCARE (Sep. 27, 2013), http://www.fiercemobilehealthcare.com/story/vcinvestment-mhealth-surpasses-last-year/2013-09-27.
73. Id.
74. FDA,
Premarket
Notification
(510k),
http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyou
rdevice/premarketsubmissions/premarketnotification510k/default.htm (last visited
Mar. 6, 2015).
75. Felasfa Wodajo, How the iPad radiology app MobileMIM became the first to get
FDA approval: Interview with CTO Mark Cain, iMEDICALAPPS (Apr. 11, 2011),
http://www.imedicalapps.com/2011/04/how-the-ipad-radiology-app-mobilemimbecame-the-first-to-get-fda-approval-interview-with-cto-mark-cain/.
76. Id.
77. Id.
78. Id.
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like implants.”79 The company resubmitted the 510(k) application, worked
towards addressing the FDA’s concerns, and eventually got the FDA
clearance a year and a half after resubmitting. While interoperability and
wide reach are essential in mHealth, the manufacturers of MIM decided to
stick with iOS and not release an Android version as well, despite the fact
that Android currently dominates the market.80 The decision was based on
how difficult it was to get FDA clearance for the iOS app, and “it became a
time and resource issue.”81
Over the past ten years, the FDA has cleared about 100 mobile apps
through the 510(k) process,82 and according to the FDA it has taken on
average 67 days for an app to get clearance. 83 This seems to be good news,
given that the time for clearance was almost 30 days below the estimated
90 days, but the FDA does point out that the duration of the clearance
process “depends on the complexity and functionality of the app.”84 While
these numbers are encouraging at first sight, Stanford’s survey points out
that technology companies in the US have experienced on average a wait
time between 10 and 31 months to obtain the 510(k) clearance.85
Mobile devices have brought about a variety of exciting new
possibilities for patient care and wellness, but new can also be problematic
in terms of conquering the 510(k). Introducing whole new functions that
were not available on a predicate device, such as monitoring parameters in
the user’s proximity, and taking them into account when giving the user
feedback, can make it difficult for the app manufacturer to be able to claim
substantial similarity with an existent predicate device. This also means, as
proven by MIM’s example, that many app developers could find
themselves walking a very fine line between having their device classified
as a Class II or Class III device, not because of a high-risk app, but because
of the novelty of the app’s features and capabilities.

3. Mobile Apps as Class III Medical Devices
Premarket approval (PMA) is the answer to a better, safer device. The
overarching approach applied for medical devices in general encourages
the right behavior, but there is a caveat. It only “speaks” to the traditional
79. Id.
80. Tony Bradley, Android Dominates Market Share, But Apple Makes All The Money,
FORBES
(NOV.
15,
2013),
http://www.forbes.com/sites/tonybradley/2013/11/15/android-dominates-marketshare-but-apple-makes-all-the-money/.
81. Wodajo, supra note 75.
82. Carolyn Wang, FDA Mobile Medical App Tweetchat: #FDA #YayMe, WCG
WORLD (Sep. 26, 2013), http://blog.wcgworld.com/2013/09/fda-mobile-medicalapp-tweetchat-fda-yayme.
83. Id.
84. Id.
85. Makower, supra note 71, at 22.
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manufacturer of medical devices – the big corporations such as Medtronic,
Phillips etc. While especially in light of the Supreme Court’s decision in
Riegel, medical device manufacturers are encouraged to go after premarket
approval, the process is complicated and expensive. As part of the
premarket approval process, manufacturers are required to submit clinical
data supporting the application and the process of gathering this data
requires the types of financial and logistic resources that the average app
developer does not possess.
Getting PMA approval is a time consuming process, which can be a
major obstacle for a technology company. According to Stanford
University’s study, while the FDA reported PMA review time is 9 months,
it took survey participants on average 54 months to obtain PMA approval
from the FDA.86 According to the same study, “the average total cost from
concept to approval [for a PMA] was $94 million, with $75 million spent
on stages linked to the FDA.”87
By definition, Class III equals innovation – any new device that has
not been marketed and does not have a predicate device would be classified
as a Class III device. It also provides the ideal scenario for a business to be
innovative – innovation will be rewarded once the device obtains the
premarket approval and becomes immune to legal action for personal
injury, which has put a huge number of manufacturers out of business (see
silicone implants, or facial prosthetics in the 1980s and 1990s).88 But
companies leading the space of traditional medical devices are large
corporations. Any start-up that develops mHealth apps would probably
love to go after premarket approval and benefit from the protection offered
by the decision of the Supreme Court in Riegel, but the vast majority
simply cannot. For the average app developer, premarket approval is a
prohibitive process and, in virtually all situations, not a real option.

B. Effects of FDA Regulation on Innovation
While the FDA stated that it intends to foster innovation in the
promising field of medical mobile apps, the guidance regarding mobile
apps does not live up to that goal. It is great news that the FDA does not
intend to regulate certain types of health related mobile apps, but the
document it released in September 2013 applies a medical device “cookiecutter” approach to mobile medical apps, which is hardly the type of
solution that will encourage app developers to innovate. As history proves,
many times it is not big corporations that drive innovation, but start-ups.
Microsoft, Apple and Google were all started by a handful of people in a
garage office. The game-changers in the field of mobile medical apps can
be anybody from a computer-science college student, to a doctor, or a small
86. Id. at 23.
87. Id. at 28.
88. Charles A. Homsey, How FDA Regulation and Injury Litigation Cripple the
Medical Device Industry, CATO Institute, Aug. 28, 2001, available at http://
www.cato.org/pubs/pas/pa412.pdf.
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company with a couple of employees. Almost none of these app developers
would have the necessary resources to go through the lengthy and
exorbitant premarket approval process.
Mobile medical apps would likely be classified as a Class III device
simply because of the degree of innovation manufacturers are able to
incorporate, not because they are all life-threatening devices. A mobile app
that would control a pacemaker, or other implantable devices, would most
likely qualify as a Class III device and would have to undergo the PMA
process. But what should qualify a mobile medical app as a Class III device
should only be the level of risk to patients, not its sheer novelty. In the
current approach employed by the FDA, which “emphasizes risk over
benefit,”89 a mobile medical app that would perform the features of a blood
pressure monitor, and therefore could go the 510(k) route, but that can also
take into account parameters such as humidity, temperature, altitude, and
activity level when analyzing the results of your blood pressure readings,
would likely have to go through the PMA process. Just because a predicate
device couldn’t employ these features at the time, should not be reason
enough to delay the timely development of such medical mobile apps that
would not only be an incredible improvement on existent traditional
medical devices, but could also provide patients with vital life-saving
information in a timely manner. What are the consequences if there is no
change? App developers would either be tempted to cut features, so they
could go after the 510(k) clearance and avoid the PMA, or not develop the
medical app at all, as the PMA would appear as an insurmountable hurdle.
The end user is the one who stands to lose the most.
In an interview with the Baltimore Sun, Chris Bergstrom, Chief
Strategy and Commercial Officer with mobile medical app developer
WellDoc, pointed out that developers will have to decide “whether they
want to seek FDA approval for something that will diagnose or help treat a
disease, of if they will develop something geared towards entertainment
and wellness.”90 Similarly, Orrin Franko, doctor, app developer and
founder of the Journal of Mobile Technology in Medicine, told USA Today
that “app developers with products that are not strictly medical … may
avoid making medical claims in their marketing in order to skip the FDA
process.”91 The financial incentives are pointing developers away from

89. Sharon Stevenson, Managing Director Okapi Venture Capital, Testimony on the
Impact of Medical Device and Drug Regulation on Innovation, Jobs and Patients:
A Local Perspective before the U.S. House of Representatives Committee on
Energy & Commerce, Subcommittee on Health (Sep. 26, 2011), available at
http://www.nvca.org/index.php?option=com_docman&task=doc_download&gid=
793&ei=fWEmU8naC8zwoATnrIHQAw&usg=AFQjCNEyw4qINcPBGZE5GX3
yW7H_kfS2sA&bvm=bv.62922401,d.cGU.
90. Carrie Wells & Tony Clarke, Baltimore Firm Welcomes FDA's Final Rules on
Mobile
Medical
Apps,
The
Baltimore
Sun,
Sep.
23,
2013,
http://www.baltimoresun.com/business/bs-bz-welldoc-apps20130923,0,4040215.story.
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going after FDA approval, as “going from zero to mobile application is
often not the most straightforward, or even worthwhile, road.”92
Technology is fast moving and the FDA is historically the opposite of
that. That is one of the reasons that created the confusion regarding
enforcement discretion and how it would apply in the case of breathalyzers
discussed in Part II.93 The initial draft released by the FDA in 2011 brought
more confusion than clarity.94 The agency did manage to clarify some of
the confusion with the newly released document (it clarified FN 13 that
referred to apps over which FDA would exercise enforcement discretion as
mobile medical apps; it provided more examples for each category of apps,
and changed its opinion regarding some apps that perform basic clinical
analysis such as an Apgar score app, which under the draft guidance would
have been regulated, but under the final guidance document will not).95
However, it took the FDA two years to come up with the final document,
and the biggest flaw of the document is that it treats apps as it would
traditional medical devices, without taking into account the particularities
of the industry.
Mobile medical app developers spoke before the House Subcommittee
on Health and Technology in June 2013 about the obstacles they face,
especially from a regulatory standpoint, warning Congress that “[w]ith the
possibility of unintended consequences disproportionately affecting small
businesses, it’s important for Congress to move carefully when making
changes that affect health care mobile technologies.”96 As the final
91. Jenny Gold, FDA Regulators Face Daunting Task as Health Apps Multiply, USA
Today, Jun. 27, 2012, http://usatoday30.usatoday.com/news/health/story/2012-0622/health-apps-regulation/55766260/1 (explaining the difficulties of monitoring
health apps and developing guidelines thereof faced by the FDA)..
92. Chris Wiltz, Pick a Good Problem: Mobisante's Approach to Mobile Health,
MOBILE DEVICE AND DIAGNOSTIC INDUSTRY ONLINE (Nov. 5, 2013),
http://www.mddionline.com/article/pick-good-problem-mobisantes-approachmobile-health (providing author’s suggestion for developing an mHealth
application or device within the small space granted by the FDA).
93. The decision to take a number of devices off the reserved devices list was reached
in 2011, but it still hasn’t been made the law, which explains why all those devices
still appear on the reserved list indicating that 510(k) clearance is required.
94. Scott D. Danzis & Christopher Pruitt, Rethinking the FDA's Regulation of Mobile
Medical Apps, 9 THE SCITECH LAWYER, no. 3, 2013, at 26,
http://www.cov.com/files/Publication/56c8d97e-4432-4623-b81c1230545cc204/Presentation/PublicationAttachment/cb8b13fe-9b8f-4de4-b8d315096d3b25be/Rethinking_the_FDA’s_Regulation_of_Mobile_Medical_Apps.pdf
(describing the FDA’s historic policies on software and puts forth draft guidance
on mobile medical apps, suggesting a balance regulatory approach).
95. Id.
96. Chris Wiltz, Medical App Developers Tell House Committee of Major Challenges,
MOBILE DEVICE AND DIAGNOSTIC INDUSTRY ONLINE (Jul. 2, 2013),
http://www.mddionline.com/article/medical-app-developers-tell-house-committeemajor-challenges (relating content from when mobile medical app developers
spoke before the House Subcommittee on Health and Technology about challenges
they face bringing their products to fruition).
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document had not been released yet, the small business representatives
stressed during the same meeting the “immediate need for clear,
comprehensive FDA guidance.”97 Once the document was released, health
IT groups welcomed it, but also pointed out its flaws.
Joel White, Executive Director of the Health IT Now Coalition,
explained that “many app developers are not opposed to regulation, but
they believe the FDA process, [which was created when the floppy disk
was around,] doesn’t fit the industry.”98 The Health IT Now Coalition
stated in a news release that the FDA “endorsed an old framework,”99 and
that “the administration and Congress ought to work together on updating
the 1970s era law to meet the needs of the 2013 … mobile health
community.”100
The mHealth Regulatory Coalition, while welcoming the much-needed
FDA guidance, pointed out that “the final guidance is fundamentally like
the proposed guidance [of 2011], and omits some very important areas.”101
Members of the Digital Health Coalition voiced the same concerns. Marc
Monseau, Managing Partner with Mint Collective referred to the questions
left unanswered by the document, “[in] particular, … [the lack of] a precise
definition of which app will be regulated, [and] … the exact meaning of an
accessory to a medical device.”102 Robert Palmer, Managing Partner with
Juice Pharma Worldwide, expressed the same concerns that seem to
pervade the mobile medical app field: “potential unintended consequences
that could inhibit innovation and add to the time and expense of bringing
new apps to market.”103
A lot of questions still remain. What happens when the manufacturer
of a completely new medical mobile app obtains premarket approval, and
then releases an update to the app? Does he have to get a 510(k) clearance
for every update? What if the new update introduces completely new
features that impact the ability to claim substantial similarity? Even when
referring to software updates to traditional medical devices, the FDA
97. Id.
98. Gold, supra note 91.
99. Press Release, Health IT Now Coalition, Health IT Now Coalition Issues
Statement
on
FDA
Final
Guidance
(Sep.
24,
2013),
http://www.healthitnow.org/health-it-now-coalition-issues-statement-on-fda-finalguidance (containing statement issued by FDA concerning final guidance to
developers of mobile medical applications)..
100. Id.
101. Greg Slabodkin, FDA Final Mobile Medical App Guidance Mirrors 2011 Draft,
FIERCE
MOBILE
HEALTHCARE
(Sep.
23,
2013),
http://www.fiercemobilehealthcare.com/story/fda-final-mobile-medical-appguidance-mirrors-2011-draft/2013-09-23?utm_source=feedly.
102. DHC Reaction to FDA Final Mobile Medical Apps Guidance, DIGITAL HEALTH
COALITION (Sep. 26, 2013), http://digitalhealthcoalition.org/publications/dhcreaction-to-fda-final-mobile-medical-apps-guidance/.
103. Id.
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seemed to indicate that it is difficult to say when a new 510(k) is
needed.104Mobile apps are different. Frequent updates are a staple of any
existing mobile app. Updates are not triggered just by the constant
advancement of technology in the field of mobile devices, but also by the
ease with which a mobile app can be modified and updated. Traditionally, a
modification in a medical device is a process that can take years, while a
developer can change a mobile app in a matter of hours. Mobile apps are
“updated and created on a daily basis, …[and the] lifecycle [of a mobile
app] is dramatically different.”105
Treating health-related mobile apps the same as medical devices
hampers app developers in the US and foreign app developers who would
like to enter the US market. In the end, by blocking or delaying innovation,
the ones who will suffer the most will be US consumers. But the Internet
provides patients with access to apps that the FDA does not reach. This is a
high risk, both for consumers and app developers. Where app developers
outside the reach of the FDA become the main provider of mHealth
solutions for US patients, and patients end up using apps that are
potentially not subject to any kind of safety regulation, consumer safety is a
big issue. At the same time, the FDA’s slow response time, lack of
transparency, and its increasingly risk-averse attitude towards new
products,106 makes it more difficult for US producers to compete with
foreign producers, and provides incentives for US companies to launch and
market their apps on foreign markets for a quicker and safer return on
investment.
While testifying in front of the U.S. House of Representatives in
September 2011, Sharon Stevenson, on behalf of the National Venture
Capital Association, emphasized that as a consequence of growing
regulatory challenges “[w]e are seeing [investors] moving away from [life
sciences companies] … [and] sending private investment dollars previously
dedicated to U.S. companies to start ups overseas, or [making plans] to
commercialize their products outside of the U.S., …as genuine ongoing
businesses.”107 Stevenson cited “the uncertain regulatory environment of
the FDA”108 as the number one factor contributing to the decrease in
venture capital investments in the development of new therapies and
technologies related to life sciences. The lack of available funding in life
sciences has had a significant impact on biotechnology startups especially,
104. See Department of Health and Human Services, Office of Device Evaluation,
510(k) Memorandum #K97-1, Food and Drug Administration: Deciding When to
Submit a 510(k) for a Change to an Existing Device (Jan. 10, 1997), available at
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDoc
uments/ucm080235.htm (“The major difficulty lies in sorting out which of these
changes is significant enough to trigger the need for a 510(k)”).
105. Gold, supra note 91.
106. Makower, supra note 71, at 24-25.
107. See Stevenson, supra note 89.
108. Id.

62

Journal of Law, Technology & the Internet · Vol. 6 · 2015
The FDA Guidance Documents for Medical Mobile Apps and its Impact on Innovation

which, like mobile app development companies, tend to have fewer
resources than large players. As a direct consequence of the decline in
venture capital investments, “[t]here were only 15 first-time biotech
financings nationally in the third quarter of 2012, which continue[d] a year
long decline.”109 Carl Weissman, the CEO of Accelerator, a venture-backed
biotech incubator, called 2012 “the saddest period in biotech.”110 As
exciting as the new field of mHealth is, if the regulatory hurdles
discouraged investors from backing biotech companies, the same fate
awaits mHealth players, who desperately need funding to be able to take on
the “FDA challenge.”

IV. SOLUTIONS
While the FDA was praised for not telling us how to innovate,111 the
FDA has not told us nearly enough about health-related apps to reach the
goal of both protecting consumers and supporting innovation. The guidance
document should not just mimic the system used for medical devices.
While the FDA has had a sinuous history in its attempt to regulate
software,112 it cannot simply address this using a cookie-cutter approach.
There is an argument that following the existing approach allows
developers to at least consider how the FDA has treated medical devices in
the past, and provided the FDA with a solution to keep its promise and
deliver the final document before the end of 2013, the document in its
current form should only be a temporary solution. It provided answers to
some questions, it clarified some aspects that were not clearly defined in
FDA’s 2011 attempt, and it was overall a positive move for the developer
community that had dealt with a lot of uncertainty in the recent years, and
more questions than answers. And while positive effects such as “more
money, resources and energy devoted to the development of mobile
apps,”113 will soon follow or have already started to show, the FDA will
have to embrace and be able to reflect change in order to be able to keep its
promise and encourage innovation.
Some stakeholders have suggested that medical mobile apps should be
treated as a separate new category with its own rules that take into account
the realities of the software development industry. Joel White, executive
director of the Health IT Now Coalition suggested that “the government set
up a new regulatory framework for mobile health – something like the
National Transportation Safety Board – to accommodate the speed,
flexibility and innovation on this new marketplace.”114 Not everyone agrees
109. Luke Timmerman, The Few and the Proud: The Biotech Startup Class of 2012,
XCONOMY (Nov. 26, 2012), http://www.xconomy.com/national/2012/11/26/thefew-and-the-proud-the-biotech-startup-class-of-2012/.
110. Id.
111. Manos, supra note 22.
112. See generally Danzis, supra note 94.
113. Digital Health Coalition, supra note 102.
114. Gold, supra note 91.
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with this approach, though. In a white paper by Epstein Becker & Green,
member of the mHealth Regulatory Coalition, the law firm argues that
“[a]s technology and the marketplace move toward convergence, [it] would
be a terrible time for regulation to move toward divergence.”115 However,
there is no denying that health IT is changing the face of healthcare as we
know it, and this change needs to be reflected in the regulatory framework
fast.
Before any structural change is implemented, a quick fix would be to
elaborate in order to simplify, by expanding right away on the current
guidance document and specifying which mobile medical apps would be
considered Class II or Class III devices. The Agency should follow the
same approach that was used to down-classify some medical device data
systems from Class III to Class I116 , in order to prevent the absurd situation
where an innovative mobile medical app that poses no risk to patients
would be classified as a Class III device by default because of its novelty
and capabilities.
As pointed out by the National Venture Capital Association, the
“adoption of a more flexible benefit-risk paradigm [would allow for]
differentiation in the level and amount of evidence required.”117 The
NVCA also urges the FDA to adopt a “qualitative framework for benefitrisk assessment … that incorporates robust input from stakeholders,
including patients and consumers.”118 A more flexible risk-benefit
paradigm would definitely have a positive impact on the approval process
for mobile medical apps as well.
Another option to speed up the process and support developers would
be to implement new premarket approval requirements for mobile medical
apps, which should be very different than the ones used for traditional
medical devices. “[Developers] thrive in an environment in which change
is constant …, and changing that culture and environment by imposing
regulatory obligations that would dramatically lengthen the product
lifecycle would have a tremendous stifling impact [on them].”119 This field,
which is constantly changing and evolving, cannot be forced to fit
successfully into a regulatory scheme created over 40 years ago. A
possibility to try to close the gap would be to create a version of the 510(k)
115. Epstein Becker & Green, P. C., Enhancing Innovation in e-health through a
Systems Approach to Regulation: A Blueprint for FDA Modernization (Aug. 2013),
available at http://op.bna.com/mdw.nsf/id/plon-9azpad/$File/EBGpaper.pdfEpstein
white paper.
116. Medical Device Data Systems, 76 Fed. Reg. 31, 8637 (Feb. 15, 2011) (codified at
21 C.F.R. § 880) (Reaching the conclusion that “general controls provide a
reasonable assurance of safety and effectiveness for this device type,” the FDA
reclassified medical device data systems from Class III (subject to premarket
approval) to Class I (subject to general controls) on February 15, 2011).
117. See Stevenson, supra note 89.
118. Id.
119. Id.
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that is more responsive to the needs and realities of this market, as well as
implement a system similar to the Accredited Persons Program used to
improve the efficiency and the timeliness of the 510(k),120 where the
accredited partners would be centers that are able to test and approve the
apps, in a simpler and faster manner than the premarket approval process
used for medical devices. This is an exciting new field, and these are
“transformational times in American health care,”121 which offer a great
opportunity for the FDA to “take a decentralized for profit approach to
mobile health application approval.”122
Regardless of how it does it, the FDA will have to start implementing
the kind of changes that prove it understands the extraordinary role it plays
in the success of modern healthcare, which is more and more focused
around e-health.
CONCLUSION
The FDA guidance document for medical mobile apps is a step in the
right direction that analysts welcomed. Nevertheless, the field of mHealth
requires more guidance specifically tailored to respond to the needs of the
players driving this field forward, and ultimately respond to the needs of
the modern patient. The guidance document is still too ambiguous and the
examples it includes are not enough to answer all the questions app
developers might have regarding whether or not the FDA will regulate their
apps. This ambiguity may ultimately lead to stifling the innovation the
FDA wants to promote, through a self-policing process that, together with
the limited resources available to the average mobile app developer, may
result in an over-simplification of medical mobile apps or even in
developers delaying or deciding not to develop complex medical mobile
apps altogether, to the detriment of the end user.
While applying the same approach it took to regulating traditional
medical devices to medical mobile apps offered the agency a fast solution
to start the conversation about medical mobile apps, the FDA needs to
continue this conversation by listening to all stakeholders, including
doctors and patients, and working closely with other agencies, such as the
FCC, to develop a coherent regulatory framework for mHealth, one that
recognizes the significant differences between medical mobile apps and
traditional medical devices. Working towards the goal of promoting
innovation, while ensuring patient safety, the FDA should provide
120. FDA,
Medical
Devices
Third
Party
Review,
http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyou
rdevice/premarketsubmissions/thirdparyreview/default.htm (last visited Mar 16.
2014).
121. Wiltz, supra note 96 (quoting Keith Brophy, CEO of Ideomed).
122. Alex Krouse, Note, Ipads, Iphones, Androids, and Smartphones: FDA Regulation
of Mobile Phone Applications as Medical Devices, 9 IND. HEALTH L. REV. 731,
763 (2012).
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developers not only with the proper regulatory framework, but also with
the tools that would help them navigate it, and with solutions realistically
tailored to put safe mHealth solutions in the hands of patients in the
shortest time possible. Given the novelty of the field and the specific
characteristics of mobile apps, the FDA should develop a platform focused
on primarily assessing the risks related to medical mobile apps and create
the premises to bring in entities with knowledge and expertise in the field
of mHealth to evaluate and certify medical mobile apps in a manner that
takes into account the realities of this new and exciting field. This would
prevent situations where medical mobile apps that pose minimal or no risks
to patients would be qualified as Class III medical devices simply because
of the novelty of the features they incorporate, and would provide a
solution that moves as fast as this new industry does, to the benefit of all
players.
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